Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer

Shen, Mengjia; Yang, Libo; Lei, Ting; Zhang, Peichuan; Lin, Xiao; Cao, Shiyu; Chen, Fei; Li, Li; Yan, Feng; Bu, Hong

doi:10.1111/jcpt.13580

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2B, among the top 50 DEGs, CA12 and TFF3 were found to be signi cantly increased in BC patiences who often showed worse NAC e cacy. The high and correlated expression of CA12 and TFF3 in estrogen receptor-positive BC may play a role in reducing the tumor's sensitivity to chemotherapy drugs such as adriamycin and docetaxel, which in turn can negatively impact the e cacy of NAC [19].…”

Section: Resultsmentioning

confidence: 99%

Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancer

Ran

Guo²,

Pan

et al. 2023

Preprint

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) is a well-established treatment modality for locally advanced breast cancer (BC). However, it can also result in severe toxicities while controlling tumors. Therefore, reliable predictive biomarkers are urgently needed to objectively and accurately predict NAC response. This study aims to integrate single-cell and bulk RNA-seq data to identify key regulatory factors that contribute to NAC response in BC patients. In specific, we construct an NAC prognostic risk model based on the nine identified prognostic NAC response-related genes and demonstrate its clinical independence and generalizability. Additionally, we explore the underlying cancer hallmarks and microenvironment features of this NAC response-related risk score, and further assess the potential impact of risk score on drug response. In summary, our study involved the development of prognostic biomarkers for NAC in BC, which was accomplished through the integration of single-cell and bulk RNA data. The results of our study are of crucial significance in the prediction of the efficacy of NAC in BC, and may have implications for the clinical management of this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancer

Ran

Guo²,

Pan

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma

Guo,

Tan,

Huang

et al. 2023

Cancer Letters

View full text Add to dashboard Cite

Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer

Zhang,

Feng,

Guo

et al. 2023

BMC Med Genomics

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) is a well-established treatment modality for locally advanced breast cancer (BC). However, it can also result in severe toxicities while controlling tumors. Therefore, reliable predictive biomarkers are urgently needed to objectively and accurately predict NAC response. In this study, we integrated single-cell and bulk RNA-seq data to identify nine genes associated with the prognostic response to NAC: NDRG1, CXCL14, HOXB2, NAT1, EVL, FBP1, MAGED2, AR and CIRBP. Furthermore, we constructed a prognostic risk model specifically linked to NAC. The clinical independence and generalizability of this model were effectively demonstrated. Additionally, we explore the underlying cancer hallmarks and microenvironment features of this NAC response-related risk score, and further assess the potential impact of risk score on drug response. In summary, our study constructed and validated a nine-gene signature associated with NAC prognosis, which was accomplished through the integration of single-cell and bulk RNA data. The results of our study are of crucial significance in the prediction of the efficacy of NAC in BC, and may have implications for the clinical management of this disease.

show abstract

Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer

Cited by 3 publications

References 39 publications

Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancer

Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancer

Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma

Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer

Contact Info

Product

Resources

About